Overview
Diabetic neuropathy is a complication related to diabetes in which the human nerve system gets affected. It is a progressive condition that gets worse with increasing symptoms over a period of time.
Approximately half of all people with diabetes have some nerve injury. It’s more common among people who’ve had diabetes for a long time, and it can lead to various health concerns down the road, lowering your quality of life. Patients are at risk for injury to their insensate feet if they are not diagnosed and preventive foot care is not provided.
Distal symmetric polyneuropathy (DSPN) and diabetic autonomic neuropathies, notably cardiovascular autonomic neuropathy (CAN), are the most researched types of diabetic neuropathy. Because there are no medications that target the underlying nerve damage, diabetes prevention is essential. Diabetic neuropathy screening is critical in clinical practice since it can detect the earliest stages of neuropathy and allow for early intervention.
Report Key Takeaways
Recommended Medications/Treatments for Diabetic Neuropathy:
While no curable treatment is available for diabetic neuropathy, there are some therapies you can think of undergoing to handle some of the symptoms effectively.
- Duloxetine is an antidepressant that proves to be beneficial for patients with diabetic neuropathy discomfort. Desipramine and Nortriptyline are the commonly used tricyclic antidepressants useful for this purpose.
- People struggling with diabetic neuropathy can take gabapentin, pregabalin, and carbamazepine as medications that can help.
- Medications can also aid in the management of autonomic neuropathy’s distressing symptoms. For instance, anticholinergic and antispasmodic can help avoid urine incontinence.
Recent Developments Related to Diabetic Neuropathy
The Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services have been launched by Orpyx® Medical Technologies Inc. (Orpyx). This remote monitoring platform fosters engagement and expands mobility for those living with diabetes by revolutionizing patient care through real-world patient data, analytics, and coaching.
Medtronic’s IntellisTM rechargeable neurostimulator and VantaTM recharge-free neurostimulator have been approved by the Food and Drug Administration (FDA) for managing pain associated with diabetic peripheral neuropathy. According to the agency’s recommendations, a stimulation trial should be done to confirm sufficient pain alleviation before permanent SCS implantation.
According to a recent study, vitamin E rich in tocotrienols may help reduce the course of diabetic retinopathy. The active therapy employed by the researchers was ExcelVite’s EVNol SupraBio. Researchers looked at how retinal microhaemorrhages and diabetic macular edema progressed in patients at baseline, two months, six months, and a year after starting treatment. EVNol SupraBio was extensively researched for other diabetes problems such as diabetic neuropathy and nephropathy, in addition to diabetic retinopathy.
Major Players Working on Diabetic Neuropathy
Hoffmann-La Roche Ltd, Astellas Pharma US, Inc., Pfizer. Inc, Abbott, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and other prominent players have a strong presence in the research and development arena related to diabetic neuropathy.
Key Reasons to Purchase This Report
- The Pipeline Insights give you a quick overview of the drug pipeline and a forecast for pipeline drugs in different regions.
- The research report goes into great detail regarding recent clinical studies and the companies conducting them.
- By reading the research study findings, the reader will better understand the disease, learn about the different treatments in development, and keep up with current industry developments.
